BACKGROUND: Research on pharmacotherapy received by individuals with body dysmorphic disorder (BDD), a relatively common and impairing disorder, is very limited. METHODS: We examined past and current pharmacotherapy received by 151 individuals with BDD who were recruited from diverse sources. RESULTS: 72.9% of subjects had received psychotropic medication. The most common type ever received was an SRI (65.6%), followed by non-SRI antidepressants (41.1%) and benzodiazepines (27.2%). Subjects with greater lifetime impairment due to BDD were more likely to have received pharmacotherapy, and subjects with lifetime OCD or greater lifetime impairment due to BDD were more likely to have received an SRI specifically. Subjects revealed their BDD symptoms to only 41.0% of pharmacotherapists. Only 12.9% of SRI trials were considered optimal for BDD, and an additional 21.5% were considered minimally adequate. SRI trials that were considered optimal or at least minimally adequate for BDD were associated with greater improvement in BDD and less severe current BDD symptoms than non-optimal or inadequate SRI trials. CONCLUSIONS: A high proportion of individuals with BDD receive pharmacotherapy, primarily SRIs, although most SRI trials appear inadequate for BDD. SRI treatment that was considered adequate was associated with greater improvement in BDD and less severe BDD symptoms.
BACKGROUND: Research on pharmacotherapy received by individuals with body dysmorphic disorder (BDD), a relatively common and impairing disorder, is very limited. METHODS: We examined past and current pharmacotherapy received by 151 individuals with BDD who were recruited from diverse sources. RESULTS: 72.9% of subjects had received psychotropic medication. The most common type ever received was an SRI (65.6%), followed by non-SRI antidepressants (41.1%) and benzodiazepines (27.2%). Subjects with greater lifetime impairment due to BDD were more likely to have received pharmacotherapy, and subjects with lifetime OCD or greater lifetime impairment due to BDD were more likely to have received an SRI specifically. Subjects revealed their BDD symptoms to only 41.0% of pharmacotherapists. Only 12.9% of SRI trials were considered optimal for BDD, and an additional 21.5% were considered minimally adequate. SRI trials that were considered optimal or at least minimally adequate for BDD were associated with greater improvement in BDD and less severe current BDD symptoms than non-optimal or inadequate SRI trials. CONCLUSIONS: A high proportion of individuals with BDD receive pharmacotherapy, primarily SRIs, although most SRI trials appear inadequate for BDD. SRI treatment that was considered adequate was associated with greater improvement in BDD and less severe BDD symptoms.
Authors: S Saxena; A Winograd; J J Dunkin; K Maidment; R Rosen; T Vapnik; G Tarlow; A Bystritsky Journal: J Clin Psychiatry Date: 2001-01 Impact factor: 4.384
Authors: A C Leon; M B Keller; M G Warshaw; T I Mueller; D A Solomon; W Coryell; J Endicott Journal: Am J Psychiatry Date: 1999-02 Impact factor: 18.112
Authors: Katharine A Phillips; Aparna Keshaviah; Darin D Dougherty; Robert L Stout; William Menard; Sabine Wilhelm Journal: Am J Psychiatry Date: 2016-04-08 Impact factor: 18.112